JP2019187429A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019187429A5 JP2019187429A5 JP2019113661A JP2019113661A JP2019187429A5 JP 2019187429 A5 JP2019187429 A5 JP 2019187429A5 JP 2019113661 A JP2019113661 A JP 2019113661A JP 2019113661 A JP2019113661 A JP 2019113661A JP 2019187429 A5 JP2019187429 A5 JP 2019187429A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- ischemia
- cells
- cell
- hematopoietic stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 27
- 210000004027 cell Anatomy 0.000 claims 11
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 7
- 230000000302 ischemic effect Effects 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 101150066398 CXCR4 gene Proteins 0.000 claims 4
- 206010008118 cerebral infarction Diseases 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- 201000006474 Brain Ischemia Diseases 0.000 claims 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 3
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 208000029078 coronary artery disease Diseases 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010022562 Intermittent claudication Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000004700 fetal blood Anatomy 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000002818 limb ischemia Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 210000002826 placenta Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 208000017234 Bone cyst Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 206010065384 Cerebral hypoperfusion Diseases 0.000 claims 1
- 206010061762 Chondropathy Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000001034 Frostbite Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010058490 Hyperoxia Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010021519 Impaired healing Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022680 Intestinal ischaemia Diseases 0.000 claims 1
- 208000034693 Laceration Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 208000027032 Renal vascular disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000005483 chronic intestinal vascular insufficiency Diseases 0.000 claims 1
- 208000024980 claudication Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 230000009519 contusion Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 230000003073 embolic effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000000222 hyperoxic effect Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 235000015110 jellies Nutrition 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001400 myeloablative effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 208000015670 renal artery disease Diseases 0.000 claims 1
- 208000032253 retinal ischemia Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 231100000019 skin ulcer Toxicity 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Claims (13)
- 対照造血幹細胞または造血前駆細胞の基本CXCR4遺伝子発現と比較して少なくとも30倍高いCXCR4遺伝子発現を有する、ヒト造血幹細胞または造血前駆細胞。
- 前記造血幹細胞または造血前駆細胞が、基本CXCR4遺伝子発現と比較して少なくとも40倍、50倍、60倍、70倍、または80倍高いCXCR4遺伝子発現を有する、請求項1に記載のヒト造血幹細胞または造血前駆細胞。
- 前記造血幹細胞および造血前駆細胞が、造血幹細胞および造血前駆細胞の集団である、請求項1に記載のヒト造血幹細胞または造血前駆細胞。
- 前記集団が、
(a)(i)0.1%、0.5%、1%、2%、5%、10%、15%、20%、25%、もしくは30%の造血幹細胞または造血前駆細胞、または(ii)1%〜3%、70%〜80%、もしくは95%〜100%の造血幹細胞または造血前駆細胞;あるいは
(b)(i)0.10%未満、0.50%未満、1.0%未満、3%未満、5%未満、10%未満、15%未満、20%未満、または30%未満のCD34 + 細胞、(ii)少なくとも0.01%でかつ50%以下のCD34 + 細胞、あるいは(iii)少なくとも1%のCD34 + 細胞、少なくとも3%のCD34 + 細胞、少なくとも5%のCD34 + 細胞、少なくとも90%のCD34 + 細胞または少なくとも95%のCD34 + 細胞
を含む、請求項3に記載のヒト造血幹細胞または造血前駆細胞。 - 前記細胞が、投与を必要とするヒト被験体へ投与準備済みである、請求項3または4に記載のヒト造血幹細胞または造血前駆細胞。
- 前記造血幹細胞または造血前駆細胞が、治療用組成物の構成成分である、請求項1〜5のいずれか一項に記載のヒト造血幹細胞または造血前駆細胞。
- 骨髄、臍帯血、動員された末梢血、ホウォートンゼリー、胎盤、胎児血、または人工多能性幹細胞(iPSC)から得られたものである、請求項1〜6のいずれか一項に記載のヒト造血幹細胞または造血前駆細胞。
- ヒト被験体における細胞治療のための、請求項1〜7のいずれか一項に記載の細胞を含む組成物。
- 免疫学的障害または疾患の処置のための、請求項1〜7のいずれか一項に記載の細胞を含む組成物。
- 前記被験体が、乳がん、卵巣がん、脳がん、前立腺がん、肺がん、結腸がん、皮膚がん、肝がん、膵がん、または肉腫を有する、請求項8に記載の組成物。
- 前記被験体が、骨髄破壊または骨髄非破壊化学療法または放射線療法を受けている、請求項8に記載の組成物。
- 前記被験体が骨髄ドナーである、請求項8に記載の組成物。
- 急性冠状動脈症候群、急性肺傷害(ALI)、急性心筋梗塞(AMI)、急性呼吸窮迫症候群(ARDS)、動脈閉塞性疾患、動脈硬化症、関節軟骨欠損、無菌性全身性炎症、アテローム硬化性心血管疾患、自己免疫疾患、骨折、脳浮腫、脳低灌流、バージャー病、熱傷、がん、心血管疾患、軟骨損傷、脳梗塞、脳虚血、脳卒中、脳血管疾患、化学療法誘発性ニューロパチー、慢性感染、慢性腸間膜虚血、跛行、うっ血性心不全、結合組織損傷、挫傷、冠動脈疾患(CAD)、重症肢虚血(CLI)、クローン病、深部静脈血栓症、深部創傷、潰瘍治癒の遅延、創傷治癒の遅延、I型糖尿病、II型糖尿病、糖尿病性ニューロパチー、糖尿病誘発性虚血、播種性血管内凝固(DIC)、塞栓性脳虚血、移植片対宿主病、凍傷、遺伝性出血性毛細血管拡張症、高酸素傷害、低酸素症、炎症、炎症性腸疾患、炎症性疾患、傷害を受けた腱、間欠性跛行、腸管虚血、虚血、虚血性脳疾患、虚血性心疾患、虚血性末梢血管疾患、虚血胎盤、虚血性腎疾患、虚血性血管疾患、虚血再灌流傷害、裂傷、左主冠状動脈疾患、肢虚血、下肢虚血、心筋梗塞、心筋虚血、臓器虚血、変形性関節症、骨粗鬆症、骨肉腫、パーキンソン病、末梢動脈性疾患(PAD)、末梢動脈疾患、末梢性虚血、末梢性ニューロパチー、末梢血管疾患、前がん、肺水腫、肺塞栓症、リモデリング障害、腎臓虚血、網膜虚血、網膜症、敗血症、皮膚潰瘍、実質臓器移植、脊髄傷害、卒中、軟骨下骨嚢胞、血栓症、血栓性脳虚血、組織虚血、一過性脳虚血発作(TIA)、外傷性脳傷害、潰瘍性大腸炎、腎臓の血管疾患、血管の炎症性の状態、フォンヒッペル・リンダウ症候群、または組織もしくは臓器の創傷の処置のための、請求項1〜7のいずれか一項に記載の細胞を含む組成物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021156680A JP2021191311A (ja) | 2011-12-02 | 2021-09-27 | 増強された幹細胞組成物 |
JP2023017468A JP2023053019A (ja) | 2011-12-02 | 2023-02-08 | 増強された幹細胞組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161566492P | 2011-12-02 | 2011-12-02 | |
US61/566,492 | 2011-12-02 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018244311A Division JP6775568B2 (ja) | 2011-12-02 | 2018-12-27 | 増強された幹細胞組成物 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020202687A Division JP2021036918A (ja) | 2011-12-02 | 2020-12-07 | 増強された幹細胞組成物 |
JP2021156680A Division JP2021191311A (ja) | 2011-12-02 | 2021-09-27 | 増強された幹細胞組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019187429A JP2019187429A (ja) | 2019-10-31 |
JP2019187429A5 true JP2019187429A5 (ja) | 2020-01-09 |
Family
ID=48536037
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014544868A Active JP6220791B2 (ja) | 2011-12-02 | 2012-11-29 | 増強された幹細胞組成物 |
JP2017098749A Active JP6483187B2 (ja) | 2011-12-02 | 2017-05-18 | 増強された幹細胞組成物 |
JP2018244311A Active JP6775568B2 (ja) | 2011-12-02 | 2018-12-27 | 増強された幹細胞組成物 |
JP2019113661A Withdrawn JP2019187429A (ja) | 2011-12-02 | 2019-06-19 | 増強された幹細胞組成物 |
JP2020202687A Pending JP2021036918A (ja) | 2011-12-02 | 2020-12-07 | 増強された幹細胞組成物 |
JP2021156680A Pending JP2021191311A (ja) | 2011-12-02 | 2021-09-27 | 増強された幹細胞組成物 |
JP2023017468A Pending JP2023053019A (ja) | 2011-12-02 | 2023-02-08 | 増強された幹細胞組成物 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014544868A Active JP6220791B2 (ja) | 2011-12-02 | 2012-11-29 | 増強された幹細胞組成物 |
JP2017098749A Active JP6483187B2 (ja) | 2011-12-02 | 2017-05-18 | 増強された幹細胞組成物 |
JP2018244311A Active JP6775568B2 (ja) | 2011-12-02 | 2018-12-27 | 増強された幹細胞組成物 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020202687A Pending JP2021036918A (ja) | 2011-12-02 | 2020-12-07 | 増強された幹細胞組成物 |
JP2021156680A Pending JP2021191311A (ja) | 2011-12-02 | 2021-09-27 | 増強された幹細胞組成物 |
JP2023017468A Pending JP2023053019A (ja) | 2011-12-02 | 2023-02-08 | 増強された幹細胞組成物 |
Country Status (10)
Country | Link |
---|---|
US (4) | US9452186B2 (ja) |
EP (2) | EP3785767A1 (ja) |
JP (7) | JP6220791B2 (ja) |
CN (3) | CN104066837B (ja) |
AU (1) | AU2012321088B8 (ja) |
CA (1) | CA2857640C (ja) |
ES (1) | ES2836976T3 (ja) |
HK (2) | HK1198389A1 (ja) |
PT (1) | PT2785834T (ja) |
WO (1) | WO2013082243A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9452186B2 (en) | 2011-12-02 | 2016-09-27 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
ES2682255T3 (es) | 2011-12-02 | 2018-09-19 | Fate Therapeutics, Inc. | Métodos mejorados de tratamiento de isquemia |
DK2838533T3 (da) | 2012-04-16 | 2017-11-27 | Univ Case Western Reserve | Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet |
US9801863B2 (en) | 2012-04-16 | 2017-10-31 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis |
US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
US9789116B2 (en) | 2013-10-15 | 2017-10-17 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
CA2939512C (en) * | 2014-02-12 | 2023-02-28 | 7 Hills Interests, Llc | Compositions and methods to improve the homing and grafting of hematopoetic stem cells |
EP3770252A1 (en) * | 2015-01-26 | 2021-01-27 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
SG11201706041XA (en) | 2015-01-26 | 2017-08-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
US10945998B2 (en) | 2015-03-08 | 2021-03-16 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating fibrosis |
KR20180033537A (ko) | 2015-07-21 | 2018-04-03 | 더 칠드런스 메디칼 센터 코포레이션 | Pd-l1 발현 조혈 줄기 세포 및 용도 |
US20170095593A1 (en) * | 2015-10-02 | 2017-04-06 | Sharon Patricia McQuillan | Adipose-derived stem cell product |
JP2018533363A (ja) | 2015-11-04 | 2018-11-15 | フェイト セラピューティクス,インコーポレイテッド | 造血細胞分化を誘導するための方法および組成物 |
ES2953925T3 (es) | 2015-11-04 | 2023-11-17 | Fate Therapeutics Inc | Ingeniería genómica de células pluripotentes |
US11525119B2 (en) | 2016-09-06 | 2022-12-13 | The Children's Medical Center Corporation | Immune cells derived from induced pluripotent stem cell |
KR102035478B1 (ko) * | 2016-10-14 | 2019-10-23 | 제주대학교 산학협력단 | 시클레소나이드를 포함하는, 암 줄기세포 성장 억제용 조성물 |
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
US11285177B2 (en) | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
CN113069460B (zh) * | 2021-03-24 | 2022-02-08 | 兰州大学 | 哈西奈德及其衍生物用于制备治疗和/或预防脑血管疾病药物中的应用 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4839032B1 (ja) | 1964-09-11 | 1973-11-21 | ||
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5077049A (en) | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
EP0423980B1 (en) | 1989-10-16 | 2000-07-12 | Amgen Inc. | Stem cell factor |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
CA2123094C (en) | 1991-11-06 | 1999-08-10 | Paulo N. Correa | Cell culture medium |
JP2795014B2 (ja) | 1991-11-29 | 1998-09-10 | 東洋インキ製造株式会社 | 保存温度管理用インジケーター |
US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
US5442033A (en) | 1993-07-20 | 1995-08-15 | Ethicon, Inc. | Liquid copolymers of epsilon-caprolactone and lactide |
AU702871B2 (en) | 1993-08-23 | 1999-03-11 | Nexell Therapeutics Inc. | (In vitro) growth of neutrophil and megakaryocyte precursors in serum-free media |
US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
US5648331A (en) | 1994-08-26 | 1997-07-15 | G.D. Searle & Co. | Method of inhibiting tissue ischemia and reperfusion injury |
US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
US5753516A (en) | 1995-02-03 | 1998-05-19 | Heagy; Wyrta E. | Screening method for ligands of the EBI-1 receptor |
WO1996040866A1 (en) | 1995-06-07 | 1996-12-19 | Novartis Ag | Serum-free media for primitive hematopoietic cells and methods of use thereof |
US5709472A (en) | 1995-10-23 | 1998-01-20 | Lifelines Technology, Inc. | Time-temperature indicator device and method of manufacture |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
US6372796B1 (en) | 1996-11-13 | 2002-04-16 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
US6191109B1 (en) | 1997-10-31 | 2001-02-20 | Children's Hospital, Inc. | Methods of treating intestinal ischemia using heparin-binding epidermal growth factor |
DE69817995T2 (de) | 1998-01-05 | 2004-07-22 | Mitra Industries Ltd. | Flexibler, zusammenfaltbarer Blutbeutel |
IL125532A0 (en) * | 1998-07-27 | 1999-03-12 | Yeda Res & Dev | Hematopoietic cell composition for use in transplantation |
AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
US6946293B1 (en) | 1999-02-10 | 2005-09-20 | Es Cell International Pte Ltd. | Progenitor cells, methods and uses related thereto |
GB9904281D0 (en) | 1999-02-24 | 1999-04-21 | Reneuron Ltd | Transplantation |
KR20020022798A (ko) | 1999-08-13 | 2002-03-27 | 후미에 사토 | 프로스타글란딘 유도체 |
TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
BR0015781A (pt) | 1999-11-24 | 2002-12-31 | Ono Pharmaceutical Co | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea |
DE60120007T2 (de) | 2000-01-31 | 2006-11-16 | Pfizer Products Inc., Groton | Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
FR2825261B1 (fr) | 2001-06-01 | 2003-09-12 | Maco Pharma Sa | Ligne de prelevement du sang placentaire comprenant une poche de rincage |
US7179643B2 (en) | 2001-06-14 | 2007-02-20 | Reliance Life Sciences Pvt. Ltd. | Device and a process for expansion of haemopoeitic stem cells for therapeutic use |
US7625752B2 (en) | 2001-12-21 | 2009-12-01 | Mount Sinai Hospital | Cellular compositions and methods of making and using them |
EP1348758A1 (en) * | 2002-03-28 | 2003-10-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Host cells having improved cell survival properties and methods to generate such cells |
RU2205627C1 (ru) | 2002-05-30 | 2003-06-10 | Открытое акционерное общество "Косметическое объединение "Свобода" | Крем для лица, выводящий токсины |
ES2393321T3 (es) | 2002-10-10 | 2012-12-20 | Ono Pharmaceutical Co., Ltd. | Promotores de la producción de factores de reparación endógenos |
AU2004216898A1 (en) | 2003-03-04 | 2004-09-16 | Pfizer Products Inc. | Use of EP2 selective receptor agonists in medical treatment |
US20050054103A1 (en) | 2003-03-07 | 2005-03-10 | Tony Peled | Expansion of renewable stem cell populations using modulators of PI 3-kinase |
JP2007525429A (ja) | 2003-03-11 | 2007-09-06 | キューエルティー ユーエスエー,インコーポレイテッド. | 細胞スケジュール依存性抗癌剤のための処方 |
EP1613742A2 (en) | 2003-04-08 | 2006-01-11 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same |
US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
IL158868A0 (en) | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
US8328876B2 (en) | 2003-12-31 | 2012-12-11 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
JP2005220089A (ja) | 2004-02-06 | 2005-08-18 | Menicon Co Ltd | 組織等価物用パッケージ |
US20050176140A1 (en) | 2004-02-10 | 2005-08-11 | Benedict Daniel J. | Method and apparatus for cell culture using a two liquid phase bioreactor |
US7004621B2 (en) | 2004-06-17 | 2006-02-28 | Cryovac, Inc. | Method of monitoring temperature exposure |
JP4086816B2 (ja) | 2004-07-01 | 2008-05-14 | 株式会社Nec情報システムズ | Bga部品搭載基板の層数見積もり装置及び方法並びに層数見積もりプログラム |
US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
CA2581237C (en) | 2004-09-24 | 2018-11-06 | Angioblast Systems, Inc. | Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc) |
EP2626415A3 (en) * | 2004-10-25 | 2014-04-16 | Cellerant Therapeutics, Inc. | Methods of expanding myeloid cell populations and uses thereof |
US20080132543A1 (en) | 2004-10-26 | 2008-06-05 | Wha Bin Im | Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists |
WO2006078886A2 (en) | 2005-01-18 | 2006-07-27 | Irm Llc | Compounds and compositions as wnt signaling pathway modulators |
EP2428563A1 (en) | 2005-02-10 | 2012-03-14 | Regents Of The University Of Minnesota | Vascular/lymphatic endothelial cells |
JP4839032B2 (ja) * | 2005-07-13 | 2011-12-14 | 国立大学法人 岡山大学 | ケモカイン受容体作用増強剤 |
EP1951881A4 (en) | 2005-11-07 | 2009-03-11 | Gen Hospital Corp | METHODS AND COMPOSITIONS FOR MODULATING AGING OF STEM CELLS |
GB2447191B (en) | 2005-12-22 | 2011-08-03 | Es Cell Int Pte Ltd | Direct differentiation of cardiomyocytes from human embryonic stem cells |
DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
CA2641861C (en) | 2006-02-08 | 2014-12-23 | Becton, Dickinson And Company | Blood collection device, method, and system for using the same |
RU2425876C2 (ru) | 2006-03-24 | 2011-08-10 | Чилдрен'З Медикал Сентер Корпорейшн | Способ модулирования роста гематопоэтических стволовых клеток |
WO2008088379A2 (en) | 2006-07-14 | 2008-07-24 | Xcellerex, Inc. | Environmental containment systems |
US20100233135A1 (en) | 2006-08-16 | 2010-09-16 | The General Hospital Corporation | Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis |
WO2008056963A1 (en) | 2006-11-10 | 2008-05-15 | Chanil Moon | Method for proliferating stem cells with leptin |
EP2094839B1 (en) | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion of hematopoietic stem cells |
US8871752B2 (en) | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
WO2009134532A2 (en) | 2008-03-07 | 2009-11-05 | The Trustees Of Columbia University In The City Of New York | Homing in mesenchymal stem cells |
CN107523587A (zh) | 2008-11-06 | 2017-12-29 | 印第安纳大学研究与技术公司 | 增强造血干细胞植入过程的材料和方法 |
CN102245189B (zh) | 2008-12-03 | 2015-06-17 | 阿莫塞特公司 | 改善梗死区灌注的组合物以及血管损伤修复方法 |
US20120202288A1 (en) | 2009-03-19 | 2012-08-09 | Fate Therapeutics, Inc. | Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
EP2275442A1 (en) * | 2009-07-06 | 2011-01-19 | Ludwig-Maximilians-Universität München | Detection and vizualization of the cell cycle in living cells |
CN112516167A (zh) * | 2010-08-12 | 2021-03-19 | 菲特治疗公司 | 改进的造血干细胞和祖细胞疗法 |
ES2682255T3 (es) | 2011-12-02 | 2018-09-19 | Fate Therapeutics, Inc. | Métodos mejorados de tratamiento de isquemia |
US9452186B2 (en) * | 2011-12-02 | 2016-09-27 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
-
2012
- 2012-11-29 US US14/362,386 patent/US9452186B2/en active Active
- 2012-11-29 CN CN201280067558.0A patent/CN104066837B/zh active Active
- 2012-11-29 CA CA2857640A patent/CA2857640C/en active Active
- 2012-11-29 ES ES12854238T patent/ES2836976T3/es active Active
- 2012-11-29 PT PT128542388T patent/PT2785834T/pt unknown
- 2012-11-29 CN CN202011283992.5A patent/CN112410298A/zh active Pending
- 2012-11-29 WO PCT/US2012/066987 patent/WO2013082243A1/en active Application Filing
- 2012-11-29 JP JP2014544868A patent/JP6220791B2/ja active Active
- 2012-11-29 AU AU2012321088A patent/AU2012321088B8/en active Active
- 2012-11-29 CN CN202011283996.3A patent/CN112375734A/zh active Pending
- 2012-11-29 EP EP20197373.2A patent/EP3785767A1/en active Pending
- 2012-11-29 EP EP12854238.8A patent/EP2785834B1/en active Active
-
2014
- 2014-11-25 HK HK14111892.0A patent/HK1198389A1/xx unknown
-
2015
- 2015-02-27 HK HK15101989.4A patent/HK1201556A1/xx unknown
-
2016
- 2016-09-02 US US15/256,133 patent/US10172888B2/en active Active
-
2017
- 2017-05-18 JP JP2017098749A patent/JP6483187B2/ja active Active
-
2018
- 2018-12-12 US US16/218,314 patent/US11052118B2/en active Active
- 2018-12-27 JP JP2018244311A patent/JP6775568B2/ja active Active
-
2019
- 2019-06-19 JP JP2019113661A patent/JP2019187429A/ja not_active Withdrawn
-
2020
- 2020-12-07 JP JP2020202687A patent/JP2021036918A/ja active Pending
-
2021
- 2021-06-04 US US17/339,440 patent/US20220118021A1/en not_active Abandoned
- 2021-09-27 JP JP2021156680A patent/JP2021191311A/ja active Pending
-
2023
- 2023-02-08 JP JP2023017468A patent/JP2023053019A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019187429A5 (ja) | ||
JP2021036918A5 (ja) | ||
Kanji et al. | Advances of stem cell therapeutics in cutaneous wound healing and regeneration | |
Silva et al. | Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model | |
Heil et al. | A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware | |
Chacko et al. | Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells | |
Chugh et al. | Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance | |
Schächinger et al. | Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial | |
Rehman et al. | Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells | |
Lin et al. | Intramyocardial peptide nanofiber injection improves postinfarction ventricular remodeling and efficacy of bone marrow cell therapy in pigs | |
Corselli et al. | Perivascular ancestors of adult multipotent stem cells | |
Georgianos et al. | Arterial stiffness: a novel risk factor for kidney injury progression? | |
Miranville et al. | Improvement of postnatal neovascularization by human adipose tissue-derived stem cells | |
Acebes-Huerta et al. | Platelet-derived bio-products: classification update, applications, concerns and new perspectives | |
Rafii et al. | Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow–derived cells | |
JP2015504313A5 (ja) | ||
JP2015505829A5 (ja) | ||
Rana et al. | Endothelial progenitor cells as molecular targets in vascular senescence and repair | |
RU2010116271A (ru) | Ангиогенные клетки из плацентарного перфузата человека | |
RU2011111938A (ru) | Выращенные в прикрепленной к субстрату культуре клетки из ткани плаценты и их использование при лечении | |
Bruyneel et al. | Stem cell therapy for the heart: blind alley or magic bullet? | |
Selem et al. | Stem cell therapy for pediatric dilated cardiomyopathy | |
Athanassopoulos et al. | Microvessel networks in pre-formed in artificial clinical grade dermal substitutes in vitro using cells from haematopoietic tissues | |
Grimaldi et al. | Potential benefits of cell therapy in coronary heart disease | |
Maeda et al. | Impact of mesenchymal stromal cell delivery through cardiopulmonary bypass on postnatal neurogenesis |